Phenylahistin is a fungal diketopiperazine derived from isoprenylated (Phe-∆His) cyclodipeptide. The (-)-enantiomer is a cell cycle inhibitor, which can be potentially used as an antitumor agent. By contrast, the (+)-enantiomer exhibits no anti-microtubule activity. To better understand these differences which could arise from a difference of bioavailability, we investigated the interaction and metabolism of both enantiomers with mammalian cytochromes P450. We found that both enantiomers were metabolized by various isoforms of mammal P450 with a noticeable activity for the (+)-enantiomer. P450 3A isoforms were mainly responsible for this metabolism, the bioactive (-)-enantiomer being 1.5 to 8 times less metabolized than the (+)-enantiomer. Spectral analysis of the interaction with P450s revealed that (-)-phenylahistin led to a hydrophobic type I signature whereas the (+)-isomer yielded a Fe-N type II one. Structural analysis of metabolites by LC-MS/MS allowed us to characterize two major metabolites (P1 and P3) for both enantiomers. In human liver microsomal preparations, P1 was predominant in the (-)-phenylahistin metabolic profile. In contrast, (+)-phenylahistin mainly produced P3 in human microsomes and CYP3A human expressed P450s. (-)-phenylahistin proved to be less toxic on P450-rich hepatocytes than on P450-deprived KB lines. The slower metabolism of this enantiomer could account for its higher toxicity. This is strengthened by the fact that isolated metabolites of (-)-phenylahistin showed no toxic effects towards KB lines. Finally, differences of metabolism and interaction mode between both phenylahistin enantiomers and CYP3A4 were supported by in silico molecular docking calculations.
INTRODUCTION
Numerous cyclopeptides are known to have biological activities. The smallest cyclopeptides studied for their potential therapeutic effects are diketopiperazines. These compounds are mainly produced in microorganisms such as bacteria and fungi (Prasad, 1995; Demain and Fang, 2000 , for a review) but are also present in mammals where they can originate from protein degradation (Scharfmann et al., 1989) . The diketopiperazine family exhibits a large variety of biological activities, ranging from cell cycle inhibition to specific enzyme activity modulation. DMD #19919 (Delaforge et al., 2001) . In a previous work we observed that roquefortine C, an antibacterial diketopiperazine, which is also isoprenylated (Table 1) , efficiently inhibited the metabolic activities of cytochromes P450, especially those of the CYP3A and CYP1A subfamilies (Aninat et al., 2001) . A comparison with other cyclodipeptides sharing structural similarities with roquefortine allowed us to highlight the key role of the imidazolyl nitrogen atom of dehydrohistidine in the P450 inhibition process (Aninat et al., to be submitted) . Such an inhibitory effect of cytochromes P450 and other hemoproteins is well-documented for numerous N-substituted imidazole compounds (Hajek et al., 1982) , but there is only little evidence for the inhibitory potency of non substituted nitrogen histidyl derivatives (Brandes et al., 1998) . We have previously shown that, among a series of diketopiperazines bearing a histidine residue, PHL was the only one to be significantly metabolized by cytochromes P450 (Aninat et al., 2001) . The achievement of total synthesis of (+)-PHL and (-)-PHL (Hayashi et al., 2000) allowed us to study their metabolism in detail, either apart or in racemic mixture. In the present work, we studied the recognition features of the two PHL enantiomers by human cytochromes P450, compared their respective metabolism, and evaluated their inhibitory mechanisms. We determined the structure of the metabolites, and evaluated the possible impact of metabolism of PHL enantiomers on their respective cytotoxicity. Finally, the metabolism results are interpreted in the light of in silico molecular docking experiments of the two PHL enantiomers into CYP3A4 active site.
Mass spectrometry analysis.
The LC-MS/MS instrument used was an LCQ DUO Ion Trap coupled with an HPLC system from Thermo-Finnigan. LC was performed on a reverse-phase column 150 x 2.1 mm Kromasil 5C18 column. 20 µL of the 50/50 buffer/CH 3 CN solution was directly injected into the LC system. Gradient chromatography (run of 33 minutes) was performed with water/acetonitrile mixture as mobile phase (eluent A: 90/10 and eluent B: 10/90) at a flow rate of 250 µL/min. The program started with 100 % A, then B was increased from 0 to 80 % within 25 minutes and held constant for the next 3 minutes. The system was then returned to 100% eluent A, and allowed to equilibrate for 5 minutes before next injection. LC-MS/MS measurements were performed using electrospray ionization mode (ESI). ESI was performed at room temperature in negative mode, the voltage maintained at 4.5 kV and the capillary temperature at 250 °C. The collision energy was set at 30 %.
Data Fitting.
Fitting procedures have been achieved with GraphPad Prism and Excel.
Computational Details.
Ligand data. Quantum calculations were performed using the Gaussian 98 suite of programs (revision A.11; Frisch et al., 2001; Gaussian Inc., Wallingford, CT) , at the DFT level of theory, using the B3LYP hybrid functional (B3, Becke, 1993; LYP, Lee et al., 1988 ). All analyses have been achieved using the genetic algorithm implemented in Sybyl (GA Conf. search). Atomic charges have been computed on the more stable conformer at the AM1/BCC level according to the Amber protocol (Jakalian et al., 2000) using Antechamber (Wang et al., 2006) . Force field parameters and topologies of these molecules have been built-up using Antechamber in association with GAFF (Wang et al., 2004) .
Protein structure preparation for Autodock procedure. The crystal structure of CYP3A4 corresponding to entry code 1W0E (Williams et al., 2004) recovered from Brookhaven Protein Database was used. Unresolved residues have been rebuilt by homology modeling using Modeller (Marti-Renom et al., 2000) with CYP3A4 structure corresponding to entry code 1TQN (Yano et al., 2004) as template. Hydrogen atoms and Gasteiger-Hückel charges have been added using Sybyl. Lys, Arg, Asp and Glu have been ionized; the protonation state of histidines has been set to δ. Charges reported by Oda et al. (Oda et al., 2005) have been used for heme. The system has been finally minimized over 500 conjugated gradient steps.
Automated docking procedure. Automated docking was carried out using the docking program AutoDock 3.0 (Morris et al. 1998, La Jolla, CA) . AutoDockTools (ADT) was used to set up the rotatable bonds in the ligands, to parameterize the solvent model and to assign the atomic partial charges of the protein. For the heme, charges were manually assigned with published values as mentioned above (Oda et al., 2005) . The initially computed AM1/BCC charges were used for ligands. Docking maps used by AutoDock were defined by considering a grid based on a box, which include the inner active site of the cytochrome. A grid of 62, 68, and 68 points in the x, y, and z directions was built. A grid spacing of 0.375 Å and a distancedependent dielectric "constant" were used for the energetic map calculations. The Lamarckian Genetic Algorithm was used for docking search; the docked compounds were subjected to 100 runs in the AutoDock search. The maximum number of energy evaluation has been raised to 20.10 6 , the number of individuals in population has been raised to 300 and the other This article has not been copyedited and formatted. The final version may differ from this version. solvated by a TIP3 water box, the minimal distance between the protein and the border of the box was set to 12.0 Å. Three counter ions (chloride) were added to neutralize the system.
Periodic boundary conditions were used in combination with PME; for the computation of electrostatic contribution, a cut-of of 10.0 Å was used. Protein and ligand were minimized over 500 cycles while keeping the solvent molecule and counter ions frozen. The ligand was then minimized over 500 cycles, the remaining of the system being frozen. The global system was minimized over 500 cycles. Finally the ligand and its surrounding partners were minimized over 1500 cycles. For this last minimization step, a frozen belly comprising protein residues and water molecule being at least at 15 Å from the ligand was applied. The default MM-PBSA procedure was then applied for the computation of binding energies.
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RESULTS

Spectral interactions of (-)-PHL, (+)-PHL and (+/-)-PHL with P450s.
In order to determine the nature of PHL/P450 interaction(s), spectral interactions were measured by UV-Vis spectrophotometry. Difference spectra were obtained by addition of increasing amounts of (+)-PHL, (+/-)-PHL or (-)-PHL to microsomal suspensions containing 1 µM P450 from human microsomes or 0.2 µM P450 from yeast-expressed human P450. The type II difference spectrum characterized by a maximum at 430 nm and a minimum around 400 nm results from a direct coordination of one imidazolyl nitrogen atom to the heme iron atom, whereas type I difference spectrum characterized by a maximum at 390 nm and a minimum around 420 nm is indicative of a hydrophobic interaction between the substrate and the reactive center of cytochrome P450.
Addition of (+)-or (+/-)-PHL to human liver microsomes P450 led to a type II difference spectrum as viewed by difference visible spectroscopy, with K s values found at around 8 µM.
However, in the presence of yeast-expressed P450 CYP3A4, the substrate absorbance and the low absorbance of the type II spectrum did not allow precise measurement of the ∆A and Ks values. In contrast, addition of (-)-PHL to human liver microsomes led to a type I spectrum, but its low intensity did not allow precise determination of the K s value. However, in the presence of CYP 3A4 yeast-expressed human microsomes, (-)-PHL led to measurable type I spectrum with the K s value around 7 µM.
The (+)-PHL type II spectrum obtained with human liver microsomes was not stable upon iron reduction by dithionite and did not lead to significant decrease of the P450-CO spectrum.
This strongly contrasts with the well-known interaction between strong imidazole inhibitors, such as miconazole, and P450s, in which the type II spectroscopic signature is maintained under such conditions. This article has not been copyedited and formatted. The final version may differ from this version. (Heumann et al., 1982; Wrighton et al., 1985) .
Cytochromes P450-dependent metabolism. Figures 2D, 2F ), whereas a reverse trend was observed for (-)-PHL ( Figure   2E ). Kinetic parameters determined from the 0-10 min linear part of the incubation profiles are reported in Table 2 . For both enantiomers, formation of P1 and P3 displayed similar K m values. By contrast, V max values were 3 and 8 times higher for the (+)-than for the (-)-PHL enantiomer, for formation of P1 and P3 respectively. This led to similar V max /K m ratios for the P1 formation whatever the enantiomer was, whereas P3 formation was mostly favored for (+)-PHL, as indicated by the highest V max /K m ratios.
Biotransformation of PHL in human hepatic
For determination of human CYP isoform involved, inhibitory studies were performed with 2 µM ketoconazole, leading to more than 90 % inhibition of both P1 and P3 metabolite formation using (+)-, (-)-, or (+/-)-PHL. Inhibitory effects were observed for both PHL enantiomers upon incubation in the presence of 20 µM bromocriptine (one of the best CYP3A4 substrate, Peyronneau et al., 1994) . The IC 50 s of bromocriptine for P3 formation were found equal to 7.8 µM and 10 µM for (+)-PHL and (-)-PHL respectively. In addition, 10
This article has not been copyedited and formatted. The final version may differ from this version. CYP3A5 was also able to form both P1 and P3 metabolites from each enantiomer. Its activity was found 4 times lower than that of CYP3A4 as regards (+)-PHL metabolism. In contrast CYP3A5 formed larger amounts of metabolites than CYP3A4 using (-)-PHL.
Using CYP1A1 isoform, (-)-PHL was metabolized into (-)-P1 and a more polar metabolite (-)-P5 in nearly equal amounts (Table 3 ). In contrast, (+)-PHL led to 6 times more of metabolite inhibition of testosterone 6β-hydroxylation was also found for both enantiomers using human liver microsomes (data not shown). Using the same protocol, bromocriptine metabolism was only inhibited as a time-dependent manner using 100 µM of each enantiomer. Similarly, ethoxyresorufin deethylation by expressed CYP1A1 was also inhibited.
Identification of the main metabolites.
Identification of PHL metabolites was based on their HPLC retention times and mass spectra using an electrospray source or after collision in the ion trap. The mass spectrum of PHL in Effects of PHL enantiomers in human hepatocyte primary culture. In contrast to various carcinoma cell lines for which cytotoxic effects can be observed in the 0.1 µM range (Kanoh et al., 1999b) , no significant toxicity was observed using (+/-)-PHL in the 1 to 5 µM range on human hepatocytes (using the MTT test or protein amounts in the cellular layer) (data not shown). In these hepatocyte preparations, metabolite formation was observed in the culture medium at 1-hour incubation (about 60 % of (+/-)-PHL metabolized). Identification of these metabolites using LC-MS/MS analysis revealed the presence of P1, P3 and P4 metabolites in the culture medium of human hepatocytes. Glucuronide products were not observed upon analysis performed before or after glucuronidase hydrolysis (15 h, 37 °C, 5,000 IU glucuronidase, 0.1 M pH 5.2 acetate buffer). In order to check the relative toxicity of the PHL metabolites, incubations of (-)-PHL using dexamethasone-treated rat liver microsomes in the presence or absence of the NADPHgenerating system were performed. HPLC analysis showed that more than 90% of the (-)-PHL was biotransformed. The pool of metabolites purified using a SEP-PACK contained less This article has not been copyedited and formatted. The final version may differ from this version. 
Effects of PHL enantiomers in
Structural analysis of PHL : determination of conformational preferences.
The molecule of PHL may adopt several structural forms, which could be in equilibrium. In addition to its chiral center, which conducts to two enantiomers, each of them can yield a set of conformers and tautomers. On the first hand, whereas the free rotation of the isoprenyl group has a minor incidence on the shape of the molecule, the rotation around the C Depending on the orientation of the Phe residue, two conformers have been located on the potential energy surface (Figure 7 ). Isomer A, characterized by a C-C
of 172°, is found to be slightly more stable than isomer A' by 1.2 kcal.mol -1 . In A', the C-C α -C β -C ipso dihedral angle is estimated to 65°, which is in good agreement with the experimental one (70°) (Kanoh et al., 1999a) . Considering the precision of the method used for the calculation, a difference of 2 kcal.mol -1 is not meaningful; these two isomers must be considered as isoenergetic.
This article has not been copyedited and formatted. The final version may differ from this version. Docking of (-)-PHL. In the case of the (-)-PHL, two main clusters were identified (Table 4, C1-C2). In the more energetically favorable one (C1), the isoprenyl group of PHL faces heme but remains rather far from it. The distance between the heme iron atom and the C=C double bond of the isoprenyl moiety equals to 5.7 Å ( Figure 9A ). In this position, the location of the isoprenyl group prevents any interaction between the nitrogen atoms of the imidazolyl ring and the iron atom. The phenyl tail of PHL points towards the cleft located between the A and (Table 4) . Despite our different assays, no configuration corresponding to the P3 metabolite could have been generated in the docking process for (-)-PHL.
Docking of (+)-PHL.
In the case of (+)-PHL, four main clusters of positioning could have been obtained (C3 to C6 in Table 4 ). In the energetically more favorable one (C3), PHL is located on the top of the active site, bellow F'-G' and between A and B' helices (see Figure   9C ). From this positioning, the molecule can flip in the active site to two positioning close to heme. In the more favorable one (C4, Figure 9D ), both the isoprenyl insaturation and the ε- The other configuration (C5, Figure 9E ) is almost identical to the more favorable orientation found for the (-)-PHL enantiomer (C1, Figure 9A ). The main differences between these two poses rely on the orientation of the benzyl moiety of PHL and are due to the inversion of the chiral center of the Phe residue. Finally, the fourth docked structure of (+)-PHL (C6, Figure   9F ) puts the ligand phenyl groups in close vicinity to the heme reactive center and accounts for the formation of the P3 metabolite.
DISCUSSION
Previously, we reported that PHL was the only known diketopiperazine having a dehydrohistidine residue, recognized and significantly metabolized by rat liver microsomes (Aninat et al., 2001 ). We also demonstrated that, of the two PHL enantiomers, only the (-)-one exhibited cytotoxic effects (Kanoh et al., 1999c) . The question arises as to whether such differences can originate, at least in part, from non-equivalent recognition, or from metabolism by cytochrome P450, leading to different metabolic ratios.
The present results show that both PHL enantiomers are recognized by various P450 isoforms, with the highest spectral signals for CYP3A among the examined CYPs. (-)-PHL generates a hydrophobic type I difference spectrum whereas (+)-PHL gives a Fe-N type II and not a reverse type I as we already reported (Aninat et al., 2001 ). All results demonstrate unambiguously that CYP3A subfamily is the most involved in the metabolism of PHL, in human liver microsomes where the CYP3A isoforms are the most abundant, or directly using Supersomes-expressed P450. Additional evidences are given by the fact that ketoconazole, a potent CYP3A inhibitor (Pelkonen et al., 1998; Zhang et al., 2002) , or bromocriptine (a good CYP 3A4 substrate, ) inhibit PHL metabolism. Metabolism of testosterone, an endogenous CYP3A substrate, was inhibited by PHL in a time-dependent manner, suggesting that both compounds compete for the CYP3A active site. In contrast, furafylline, sulfaphenazole, quinidine, and α-naphthoflavone (ANF), respectively selective inhibitors of CYP1A2, CYP2C9, CY2D6 and CYP1A (Bourrie et al., 1996; Guengerich et al., 1986; 1999) , had no signature, one can notice than the first one is supported by the metabolism rates of (+)-and (-)-PHL by expressed CYP3A4. Indeed, we have shown that the rate of production is higher for P3 production than for P1 for (+)-PHL with respect to (-)-PHL. Kinetics data obtained from human liver microsomes showed that Vmax/Km values were 7 times lower for (-)-P3
and only 2 times lower for (-)-P1 than for their corresponding (+)-metabolites. Thus, there is more discrimination between P3 and P1 formation depending on the chirality of the compound. This demonstrates that CYP3A4 does not significantly differentiate between enantiomers when they enter the enzyme via their imidazole moiety, whereas a net chiral differentiation occurs when PHL accesses to the inner pocket via its phenyl side. In other terms, the higher chiral recognition of PHL by CYP3A4 is associated with the vicinity of its asymmetrical side (Phe moiety, P3 metabolism) to the heme reactive center. In order to confirm this interpretation, we have addressed CYP3A4/PHL binding by molecular docking.
For both enantiomers, the positioning corresponding to (-)-P1 and (+)-P1, (+)-P3 and (+)-PHL
Fe-imidazole type II interaction could be characterized in silico (Table 4) . In all cases, the binding energies computed at the MM-PBSA level were found lower for the (+)-enantiomer.
This is in agreement with the experimental K s . In the case of (+)-PHL, the best MM-PBSA scoring (-88 kcal.mol -1 ) is associated to the location of the substrate in a high affinity secondary binding site, then the positioning corresponding to P1 and Fe-imidazole interaction appear to be less favorable with similar binding scores (-62 and -65 kcal.mol -1 respectively). In the case of (-)-PHL, the most favorable positioning corresponded to P1 followed by the pose B (Fe-imidazole proximity, not spectroscopically observed). Despite our effort, no structure corresponding to P3 could have been obtained via molecular docking. However, the positions found in silico are in agreement with the finding of a type I interaction and with a favored formation of P1 with respect to P3. Finally, the binding energy computed for the prepositioning of P1 of (+)-PHL ( Figure 9C ) is energetically more favorable than the one of P1
for (-)-PHL ( Figure 9A ), which accounts for the higher production rate of metabolites obtained for (+)-PHL. Hence, the type II binding signature is not in contradiction with a high metabolism activity. This is due to the fact that the molecule is linear and can enter the active site by both ends, one leading to weak Fe-imidazolyl interaction or P1 metabolite, the other to the formation of metabolite P3.
No toxicity was observed during ex vivo studies on primary cultures of rat or human hepatocytes, these cells being able to metabolize PHL. Consequently, one of the origins of the lower toxicity could result in lower reactivity of the formed metabolites on the cellular macromolecules. As a confirmation, we carried out a cytotoxicity study on KB lines with (-)-PHL and a mixture of its metabolites. The results gave evidence that the biotransformation of (-)-PHL led to an efficient detoxification. Besides, studies of biological activity of synthetic derivatives of PHL indicated that the presence of an alkyl group with proper length or a quaternary carbon at position 5 of the imidazole ring, and the spatial arrangement of the benzyl group of the phenylalanine residue, are very important for inhibition of microtubule formation activity (Kanoh et al., 1999a) . Our HPLC-MS/MS analyses demonstrate that hydroxylation of the two major metabolites P1 and P3 occurs at these two positions of the molecule, thereby leading to a loss of toxicity of the metabolites formed.
This article has not been copyedited and formatted. The final version may differ from this version. As a conclusion, CYP3A and CYP1A1 are the main isoforms involved in biotransformation of PHL and are able to discriminate between PHL enantiomers. Such discrimination has been assessed through metabolites ratios and metabolism rates. Our docking approach associated with MM-PBSA scoring agreed with the structure of metabolite produced and spectral interaction observed. It also accounted for differences in metabolite ratios and supported a mechanism of recognition. We have shown that metabolism leads to non-toxic metabolites and the differences between the two enantiomers arise from two complementary phenomena:
i) an intrinsic toxicity of the parent enantiomer (-)- ( 
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